Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:23 25/09/2026			Varia. 5j.	Varia. 1 janv.
12 552,00 ^GBX	+1,23 %		+0,42 %	-8,98 %

25/09	Les marchés européens clôturent majoritairement en hausse vendredi, portés par l’espoir d’un accord entre les États-Unis et l’Iran sur le détroit	MT
25/09	Les actions britanniques progressent, portées par le regain de confiance des consommateurs	MT

Communiqués

25/09	Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer	BU
24/09	AstraZeneca : Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session	PU
21/09	University of Dundee: Tayside team recruit first global participant in clinical trial for Chronic Kidney Disease	AQ
18/09	AstraZeneca : Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)	PU
18/09	Big Picture Bio Founded to Identify, Design and Optimise Promising Cancer Combination Therapies	AQ
18/09	Onco360(R) Has Been Selected as a National Pharmacy Partner for ETCAMAH (camizestrant)	AQ
14/09	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
14/09	TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial	BU
11/09	AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer	PU
08/09	IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer	BU
08/09	Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	BU
08/09	AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	PU
05/09	ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	BU
04/09	AstraZeneca : Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	PU
01/09	AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer	BU
01/09	AstraZeneca : Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer	PU
01/09	AstraZeneca : completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer	PU
27/08	TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	BU
20/08	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner	AQ
18/08	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	AQ
17/08	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
17/08	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO	BU
17/08	HUTCHMED Announces ORPATHYS plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer	AQ
17/08	AstraZeneca : Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	PU
17/08	AstraZeneca : Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	PU